Rational
- Present up-to-date data.
- Interpret clinical and scientific findings and predict potential impact.
- Recognize and characterize the hurdles that remain.
- Provide a vision for the future if hurdles are addressed
Presidency
Paolo A. Ascierto, Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS “Fondazione G. Pascale”, Naples, Italy
Bernard A. Fox, Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, US
Faculty
Nina Bhardwaj,
The Tisch Cancer Institute at Mount
Sinai, New York, NY, US
William Freed-Pastor,
Harvard Medical School,
Dana-Farber Cancer Institute,
Boston, MA, US
Pablo Guasp,
Memorial Sloan Kettering Cancer
Center, New York, NY, US
Rom Leidner,
Providence Cancer Institute: Earle A. Chiles Research Institute,
Portland, OR, US
Kees Melief,
Leiden University
Medical Center,
Leiden, The Netherlands
Erwei Song,
Sun Yat-sen Memorial Hospital,
Sun Yat-sen University, Guangzhou,
Guangdong,China
Ryan Sullivan,
Harvard Medical School,
Massachusetts General Hospital,
Boston, MA, US
Inge Marie Svane,
Center for Cancer Immune Therapy
(CCIT), Herlev Hospital,
Copenaghen, Denmark
Pierre Thibault,
Institute for Research in
Immunology and Cancer,
Montreal, Canada
Jonathan Yewdell,
National Institutes of Health,
NIAID/DIR, Bethesda, MD, US
Lei Zheng,
Johns Hopkins School of
Medicine, Baltimora, MD, US
Organizational Secretariat
Media Partnership
Informazioni
- October 1st, 2024 - 09.30 AM
-
NH COLLECTION MILANO CITYLIFE
Via Bartolomeo Colleoni,14 20149 Milan, ITALY -
CME COURSE
ID CME 936-426648
7 CREDITS